NuVasive

FYR Medical Receives Series A Funding to Complete Development of the Industry’s First Light Field Extended Reality Loupes—a Revolutionary Product Advancement for the Operating Room

Retrieved on: 
Tuesday, February 14, 2023
Technology, Medical Devices, Surgery, Health Technology, Metaverse, Audio, Video, Other Health, Internet, Hardware, Health, Fatigue, XR, Perception, Medicine, CT, MRI, Telehealth, Spine, NuVasive, FYR, Operating, Workflow, Medical imaging

FYR Medical, FYR Medical, Inc today announced it has raised a $2.6 million Series A funding round.

Key Points: 
  • FYR Medical, FYR Medical, Inc today announced it has raised a $2.6 million Series A funding round.
  • The device is extremely lightweight with a minimalized form factor designed to replicate the size and shape of surgical loupes.
  • FYR Medical’s XR digital loupes will first target spinal surgery, focusing on utilization with existing enabling technology platforms.
  • FYR Medical is a medical device company working to commercialize light field electro-optical technology originally invented by Lockheed Martin.

NUVASIVE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NuVasive, Inc. - NUVA

Retrieved on: 
Monday, February 13, 2023
Legal, Professional Services, Sale, NUVA, NYSE, Globus Medical, NuVasive, KSF

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (NasdaqGS: NUVA) to Globus Medical, Inc. (NYSE: GMED).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NuVasive, Inc. (NasdaqGS: NUVA) to Globus Medical, Inc. (NYSE: GMED).
  • Under the terms of the proposed transaction, shareholders of NuVasive will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

GMED Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Globus Medical, Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, February 9, 2023
Class Action Lawsuit, Other Professional Services, Legal, Professional Services, NYSE, Fraud, Globus Medical, NuVasive, Advertising, Security (finance), Globus

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Globus Medical, Inc. (NYSE: GMED) and NuVasive, Inc. is fair to Globus shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Globus Medical, Inc. (NYSE: GMED) and NuVasive, Inc. is fair to Globus shareholders.
  • Under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock.
  • On behalf of Globus shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

NUVA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NuVasive, Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, February 9, 2023
Legal, Professional Services, NuVasive, Sale, NUVA, Fraud, Globus Medical, Advertising, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NuVasive, Inc. (NASDAQ: NUVA) to Globus Medical, Inc. for 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock is fair to NuVasive shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NuVasive, Inc. (NASDAQ: NUVA) to Globus Medical, Inc. for 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock is fair to NuVasive shareholders.
  • On behalf of NuVasive shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care

Retrieved on: 
Thursday, February 9, 2023
Record, Health, Wachtell, Lipton, Rosen & Katz, Globus Medical, Spine, NUVA, ID, NYSE, EBITDA, Patient, Telephone, DSM-IV codes, BofA Securities, NuVasive, Education, Growth, SAN, Goldman Sachs, Surgeon, Elective surgery, Hospital, Pharmaceutical industry, Management, Risk management, Cryptocurrency

Following the close of the transaction, NuVasive shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis.

Key Points: 
  • Following the close of the transaction, NuVasive shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis.
  • We look forward to combining the NuVasive and Globus Medical teams to capitalize on the many opportunities to improve patient care and create sustainable shareholder value."
  • "Our combination with Globus Medical is transformative, joining two companies with highly complementary capabilities, geographic footprints and customer bases," said Chris Barry, chief executive officer of NuVasive.
  • Globus Medical and NuVasive both have strong records of developing technology that solves unmet clinical needs for the treatment of musculoskeletal disorders.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATCX, ALR, GMED

Retrieved on: 
Sunday, February 12, 2023
GI Partners, Advertising, NYSE, Fraud, Sale, Globus Medical, NuVasive, Security (finance), Globus

If you are an Atlas shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Atlas shareholder, click here to learn more about your rights and options .
  • AlerisLife Inc. (NASDAQ: ALR)’s sale to ABP Acquisition LLC for $1.31 per share in cash.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NUVA, SUMO

Retrieved on: 
Sunday, February 12, 2023
Sale, Globus Medical, Advertising, NuVasive, Fraud, Francisco Partners, Security (finance)

Sumo Logic, Inc. (NASDAQ: SUMO)’s sale to affiliates of Francisco Partners for $12.05 per share in cash.

Key Points: 
  • Sumo Logic, Inc. (NASDAQ: SUMO)’s sale to affiliates of Francisco Partners for $12.05 per share in cash.
  • If you are a Sumo shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Lifshitz Law PLLC Announces Investigations of SUMO, GMED, NUVA, and CSII

Retrieved on: 
Sunday, February 12, 2023
Laboratory, Francisco Partners, Telephone, GMED, Sale, Globus Medical, SUMO, Abbott Laboratories, Advertising, NuVasive, CSII, Hewlett, Logic, NUVA, Financial adviser, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of GMED and NuVasive, Inc. whereby NuVasive shareholders will receive 0.75 of a share of GMED Class A common stock for each share of NuVasive common stock.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of GMED and NuVasive, Inc. whereby NuVasive shareholders will receive 0.75 of a share of GMED Class A common stock for each share of NuVasive common stock.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CSII to Abbott Laboratories for $20.00 per common share.
  • ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2022 Results

Retrieved on: 
Monday, January 30, 2023
Spine, Webcast, NuVasive, SAN, NUVA, Cryptocurrency, Video game

NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m.

Key Points: 
  • NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m.
  • ET to discuss the results of its financial performance for the fourth quarter and full year ended December 31, 2022.
  • A live webcast of the conference call and supplemental financial information of the Company's fourth quarter and full-year 2022 results will be available on the Investor Relations section of the Company's website at www.nuvasive.com .
  • The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers.

Tyber Medical Names James Abraham and Damien Sibilla to Executive Leadership Team

Retrieved on: 
Wednesday, January 25, 2023
Marketing, CFO, Orthopedic surgery, Globus Medical, OEM, Financial management, NuVasive, Tap, Area, Chief commercial officer, Management, Trauma

BETHLEHEM, Pa., Jan. 25, 2023 /PRNewswire/ -- To further accelerate record growth and rapid commercialization through its OEM partnerships with leading orthopedic companies in the global trauma, extremity and spine markets, Tyber Medical LLC has tapped industry veteran James Abraham for its newly-created Chief Commercial Officer role and Damien Sibilla for the role of Chief Financial Officer. Both are serving on Tyber Medical's executive leadership team.

Key Points: 
  • Both are serving on Tyber Medical's executive leadership team.
  • Abraham and Sibilla will lead Tyber Medical's expansion through OEM partnerships at leading orthopedic companies.
  • We are thrilled to have Jim on board to take our product commercialization to the next level," said Tyber Medical Chief Executive Officer, Jeff Tyber.
  • "We are very excited to have Damien join our executive leadership team," said Tyber.